AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing ...

AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on ...

Eli Lilly: Is Another Monster Quarter Coming

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Path to First- Patient Dosing

AlphaTON Capital Corp ( Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at the AACR ...
Clinical Trials Arena on MSN

Zymeworks reports Phase I data for ZW191 ADC

"Zymeworks reports Phase I data for ZW191 ADC" was originally created and published by Clinical Trials Arena, a GlobalData ...

Novo Nordisk's Lottery Ticket Against Alzheimer's Disease

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Confe…

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...